科研之友
微信
新浪微博
Facebook
分享链接
摘要
Instead of using traditional separate phase I and II trials, in this article, we propose using a parallel three-stage phase I/II design, incorporating a dose expansion approach to flexibly evaluate the safety and efficacy of dose levels, and to select the optimal dose. In the proposed design, both the toxicity and efficacy responses are binary endpoints. A 3+3-based procedure is used for initial period of dose escalation at stage 1; at this level, the dose can be expanded to stage 2 for exploratory efficacy studies of phase IIa, while simultaneously, the safety testing can advance to a higher dose level. A beta-binomial model is used to model the efficacy responses. There are two placebo-controlled randomization interim monitoring analyses at stage 2 to select the promising doses to be recommended to stage 3 for further efficacy studies of phase IIb. An adaptive randomization approach is used to assign more patients to doses with higher efficacy levels at stage 3. We examine the properties of the proposed design through extensive simulation studies by using R programming language, and also compare the new design with the conventional design and a competing adaptive Bayesian design. The simulation results show that our design can efficiently assign more patients to doses with higher efficacy levels and is superior to the two competing designs in terms of total sample size reduction.
- 出版日期2014-1-1
- 单位中国人民解放军空军军医大学; 第四军医大学; 西安财经大学
